Voyager Therapeutics (VYGR) to Release Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Voyager Therapeutics to post earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Trading Up 1.9 %

Shares of Voyager Therapeutics stock opened at $4.31 on Wednesday. The company’s fifty day simple moving average is $5.53 and its two-hundred day simple moving average is $6.20. The company has a market cap of $235.46 million, a P/E ratio of 6.07 and a beta of 0.91. Voyager Therapeutics has a 12-month low of $4.00 and a 12-month high of $10.66.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on VYGR. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $5.73 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $9.00 target price (down from $11.00) on shares of Voyager Therapeutics in a research report on Tuesday, February 11th. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $15.72.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.